BACKGROUND: New therapeutic targets for antibiotic-resistant bacterial pathogens are desperately needed. The bacterial surface polysaccharide poly-β-(1-6)-N-acetyl-glucosamine (PNAG) mediates biofilm formation by some bacterial species, and antibodies to PNAG can confer protective immunity. By analyzing sequenced genomes, we found that potentially multidrug-resistant bacterial species such as Klebsiella pneumoniae, Enterobacter cloacae, Stenotrophomonas maltophilia, and the Burkholderia cepacia complex (BCC) may be able to produce PNAG. Among patients with cystic fibrosis patients, highly antibiotic-resistant bacteria in the BCC have emerged as problematic pathogens, providing an impetus to study the potential of PNAG to be targeted for immunotherapy against pan-resistant bacterial pathogens. METHODS: The presence of PNAG on BCC was assessed using a combination of bacterial genetics, microscopy, and immunochemical approaches. Antibodies to PNAG were tested using opsonophagocytic assays and for protective efficacy against lethal peritonitis in mice. RESULTS: PNAG is expressed in vitro and in vivo by the BCC, and cystic fibrosis patients infected by the BCC species B. dolosa mounted a PNAG-specific opsonophagocytic antibody response. Antisera to PNAG mediated opsonophagocytic killing of BCC and were protective against lethal BCC peritonitis even during coinfection with methicillin-resistant Staphylococcus aureus. CONCLUSIONS: Our findings raise potential new therapeutic options against PNAG-producing bacteria, including even pan-resistant pathogens.
BACKGROUND: New therapeutic targets for antibiotic-resistant bacterial pathogens are desperately needed. The bacterial surface polysaccharide poly-β-(1-6)-N-acetyl-glucosamine (PNAG) mediates biofilm formation by some bacterial species, and antibodies to PNAG can confer protective immunity. By analyzing sequenced genomes, we found that potentially multidrug-resistant bacterial species such as Klebsiella pneumoniae, Enterobacter cloacae, Stenotrophomonas maltophilia, and the Burkholderia cepacia complex (BCC) may be able to produce PNAG. Among patients with cystic fibrosispatients, highly antibiotic-resistant bacteria in the BCC have emerged as problematic pathogens, providing an impetus to study the potential of PNAG to be targeted for immunotherapy against pan-resistant bacterial pathogens. METHODS: The presence of PNAG on BCC was assessed using a combination of bacterial genetics, microscopy, and immunochemical approaches. Antibodies to PNAG were tested using opsonophagocytic assays and for protective efficacy against lethal peritonitis in mice. RESULTS:PNAG is expressed in vitro and in vivo by the BCC, and cystic fibrosispatients infected by the BCC species B. dolosa mounted a PNAG-specific opsonophagocytic antibody response. Antisera to PNAG mediated opsonophagocytic killing of BCC and were protective against lethal BCC peritonitis even during coinfection with methicillin-resistant Staphylococcus aureus. CONCLUSIONS: Our findings raise potential new therapeutic options against PNAG-producing bacteria, including even pan-resistant pathogens.
Authors: Leslie A Kalish; David A Waltz; Mark Dovey; Gail Potter-Bynoe; Alexander J McAdam; John J Lipuma; Craig Gerard; Donald Goldmann Journal: Am J Respir Crit Care Med Date: 2005-11-04 Impact factor: 21.405
Authors: Andrea Kropec; Tomas Maira-Litran; Kimberly K Jefferson; Martha Grout; Sarah E Cramton; Friedrich Götz; Donald A Goldmann; Gerald B Pier Journal: Infect Immun Date: 2005-10 Impact factor: 3.441
Authors: Teresa A Urban; Adam Griffith; Anastasia M Torok; Mark E Smolkin; Jane L Burns; Joanna B Goldberg Journal: Infect Immun Date: 2004-09 Impact factor: 3.441
Authors: Tami D Lieberman; Jean-Baptiste Michel; Mythili Aingaran; Gail Potter-Bynoe; Damien Roux; Michael R Davis; David Skurnik; Nicholas Leiby; John J LiPuma; Joanna B Goldberg; Alexander J McAdam; Gregory P Priebe; Roy Kishony Journal: Nat Genet Date: 2011-11-13 Impact factor: 38.330
Authors: Thomas A Russo; Janet M Beanan; Ruth Olson; Ulrike MacDonald; Andrew D Cox; Frank St Michael; Evgeny V Vinogradov; Brad Spellberg; Nicole R Luke-Marshall; Anthony A Campagnari Journal: Infect Immun Date: 2013-01-07 Impact factor: 3.441
Authors: Colette Cywes-Bentley; David Skurnik; Tanweer Zaidi; Damien Roux; Rosane B Deoliveira; Wendy S Garrett; Xi Lu; Jennifer O'Malley; Kathryn Kinzel; Tauqeer Zaidi; Astrid Rey; Christophe Perrin; Raina N Fichorova; Alexander K K Kayatani; Tomas Maira-Litràn; Marina L Gening; Yury E Tsvetkov; Nikolay E Nifantiev; Lauren O Bakaletz; Stephen I Pelton; Douglas T Golenbock; Gerald B Pier Journal: Proc Natl Acad Sci U S A Date: 2013-05-28 Impact factor: 11.205